

Statement on Intrauterine Devices, Counselling and Pain Management

Version date: December 15th, 2022

Intrauterine devices (IUDs) are highly effective and are the recommended first-line contraceptive method, yet they are underutilized. Individuals may find it difficult to navigate the breadth of information available – true, false, and incomplete - to make the best choice for their needs. Patients that could significantly benefit from IUD use, for both contraceptive and non-contraceptive benefits, may not be receiving one because of difficulty to access or limited in availability, or because information available to patients and/or healthcare providers may not be sufficient on either the complications or the benefits of IUDs.

IUD insertion can be painful for some patients. It is important that healthcare providers counsel patients about what can be expected during the IUD placement process, including pain control options. Healthcare providers should ensure that the patient has sufficient time to review information, ask questions, and provide consent.

Some patients may experience more pain or discomfort than others during IUD insertion including those who have a history of trauma, chronic pelvic pain, sexual pain, or painful periods, as well as those who are post-partum, have difficulty with or have never had speculum exams, and those who are anxious about the procedure. Even though some patients have a higher risk of pain, *it does not mean they are not good candidates for an IUD.*

Anxiety, as well as anticipated and actual pain related to the procedure, are important barriers to the use of IUDs. It is critical for healthcare providers to work together with patients to ensure a supportive, reassuring environment where the patient understands that they are in control and can request that the procedure be paused or halted at any time. The healthcare provider and patient should work together to develop an appropriate pain management plan when it is needed.

Most patients find that oral medications meet their pain management needs, but the options below have been shown to be effective and should be discussed with patients, as appropriate.

Oral Analgesics

Drug	Dose	Route of Administration	Patient	Timing	References
Ketoprofen	150mg	Oral	Parous	1 hr prior to procedure	Abbas et al ¹
Ketorolac	20mg	Oral	Nulliparous or parous	40-60 minutes prior to procedure	Crawford et al ² , Samy et al ³
Naproxen	550mg	Oral	Nulliparous or multiparous	1 hr prior to procedure	Karabayirli et al ⁴ , Ngo et al ⁵
Tramadol	50mg	Oral	Multiparous	1 hr prior to procedure	Karabayirli et al ⁴

Local Anaesthetic

Drug	Dose	Route of Administration	Patient	Timing	References
10% lidocaine	4 puffs (40mg, 10 mg/mL/puff)	Spray applied to cervix surface including external os	Parous	3 minutes prior to procedure	Aksoy et al ⁶ , Karasu et al ⁷ , Panichyawat et al ⁸
1% lidocaine	20mL	Paracervical block	Nulliparous	Prior to procedure	Mody et al ⁹
1% lidocaine	10mL	Paracervical block	Adolescents or young women (aged 14-22)	3 minutes prior to procedure	Akers et al ¹⁰
2% lidocaine	12mL (20 mg/mL)	Paracervical block	Multiparous	Prior to procedure	Karasu et al ⁷
2% lidocaine	3.6mL (72mg)	Intracervical block	Nulliparous	Prior to procedure	De Nadai et al ¹¹
5% lido-caine/ prilocaine	4mL	Cream applied to anterior cervical lip and cervical canal	Parous	7 minutes prior to procedure	Abbas et al ¹² , Samy et al ⁹ , Tavakolian et al ¹³

Although there are no data specific for effectiveness of pain relief during IUD insertion, other analgesics may also be suitable, including low dose methoxyflurane¹⁴.

IUDs are among the most effective forms of contraception. The Society of Obstetricians and Gynaecologists of Canada (SOGC) acknowledges that patients and healthcare providers may require additional information about pain management related to IUD insertion; in the majority of cases, pain and/or discomfort is manageable and should not be a barrier to using an IUD.

IUD insertion is a common rapid outpatient procedure, typically taking between 5 and 15 minutes with possible additional time if pain management is required. Complications during the insertion process are rare. IUD insertion requires a skilled healthcare provider, and the SOGC offers a preceptorship training program specific to intrauterine contraception insertion, including counselling. For more information, please visit our website: [Intrauterine Contraception \(IUC\) Insertion Preceptorship \(sogc.org\)](http://www.sogc.org/Intrauterine_Contraception_(IUC)_Insertion_Preceptorship).

All healthcare providers should remember that every contraceptive method is a way to empower patients, including specific consideration for non-contraceptive benefits.

For the development of this Statement, the SOGC would like to thank Nicole Todd, Veronique Raymond, David Rittenberg, Anisha Dubey, Olga Bougie, Joann James, Jocelynn Cook, Diane Francoeur, Allison Felker and Amanda Black for their valuable input.

References

1. Abbas AM, Ali SS, Salem MN, et al. Effect of oral ketoprofen on pain perception during copper IUD insertion among parous women: A randomized double-blind controlled trial. *Middle East Fertility Society Journal*. 2018;23:491-5.
2. Crawford M, Davy S, Book N, et al. Oral Ketorolac for Pain Relief During Intrauterine Device Insertion: A Double-Blinded Randomized Controlled Trial. *J Obstet Gynaecol Can*. 2017;39:1143-9.
3. Samy A, Abbas AM, Mahmoud M, et al. Evaluating different pain lowering medications during intrauterine device insertion: a systematic review and network meta-analysis. *Fertil Steril*. 2019;111:553-61.e4.
4. Karabayirli S, Ayrim AA, Muslu B. Comparison of the analgesic effects of oral tramadol and naproxen sodium on pain relief during IUD insertion. *J Minim Invasive Gynecol*. 2012;19:581-4.
5. Ngo LL, Braaten KP, Eichen E, et al. Naproxen Sodium for Pain Control With Intrauterine Device Insertion: A Randomized Controlled Trial. *Obstet Gynecol*. 2016;128:1306-13.
6. Aksoy H, Aksoy Ü, Ozyurt S, et al. Lidocaine 10% spray to the cervix reduces pain during intrauterine device insertion: a double-blind randomised controlled trial. *J Fam Plann Reprod Health Care*. 2016;42:83-7.
7. Karasu Y, Cömert DK, Karadağ B, et al. Lidocaine for pain control during intrauterine device insertion. *J Obstet Gynaecol Res*. 2017;43:1061-6.
8. Panichyawat N, Mongkornthong T, Wongwananuruk T, et al. 10% lidocaine spray for pain control during intrauterine device insertion: a randomised, double-blind, placebo-controlled trial. *BMJ Sex Reprod Health*. 2021;47:159-65.
9. Mody SK, Farala JP, Jimenez B, et al. Paracervical Block for Intrauterine Device Placement Among Nulliparous Women: A Randomized Controlled Trial. *Obstet Gynecol*. 2018;132:575-82.
10. Akers AY, Steinway C, Sonalkar S, et al. Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women. *Obstet Gynecol*. 2017;130:795-802.
11. De Nadai MN, Poli-Neto OB, Franceschini SA, et al. Intracervical block for levonorgestrel-releasing intrauterine system placement among nulligravid women: a randomized double-blind controlled trial. *Am J Obstet Gynecol*. 2020;222:245.e1-e10.
12. Abbas AM, Abdellah MS, Khalaf M, et al. Effect of cervical lidocaine-prilocaine cream on pain perception during copper T380A intrauterine device insertion among parous women: A randomized double-blind controlled trial. *Contraception*. 2017;95:251-6.
13. Tavakolian S, Doulabi MA, Baghban AA, et al. Lidocaine-Prilocaine Cream as Analgesia for IUD Insertion: A Prospective, Randomized, Controlled, Triple Blinded Study. *Glob J Health Sci*. 2015;7:399-404.
14. Borobia AM, Collado SG, Cardona CC, Pueyo RC, Alonso CF, Torres IP, González MC, Casal Codesido JR, Betegón MA, Barcela LA, Andicoechea AO, Testa AF, Colina JT, Dorribo AC, Del Arco Galán C, Martínez Ávila JC, Lugiilde ST, Carcas Sansuán AJ; InMEDIATE Investigators Group. Inhaled Methoxyflurane Provides Greater Analgesia and Faster Onset of Action Versus Standard Analgesia in Patients With Trauma Pain: InMEDIATE: A Randomized Controlled Trial in Emergency Departments. *Ann Emerg Med*. 2020 Mar;75(3):315-328. doi: 10.1016/j.annemergmed.2019.07.028. Epub 2019 Oct 14. PMID: 31623936.